Elmiron Eye Damage Lawsuit – What You Need to Know to File a Claim


If you’ve suffered from pigmentary maculopathy caused by a prescription drug, you may be interested in an Elmiron eye damage lawsuit. Several plaintiffs have filed such cases against Janssen Pharmaceuticals for failing to warn about the potential side effects of Elmiron. Here’s what you need to know to file a claim.

Tina Pisco’s Elmiron eye damage lawsuit

In a May 2020 lawsuit, Tina Pisco claims the drug Elmiron caused her to suffer permanent retinal damage and permanent vision loss. She first began taking the drug in 2012 for interstitial cystitis, a painful bladder condition. However, she began to experience vision problems six years later. A retinal examination revealed that she suffered permanent retinal damage in both of her eyes. Pisco is suing Janssen Pharmaceuticals and Johnson & Johnson auxiliary, which manufactured Elmiron.

Pisco’s lawsuit claims that Elmiron caused her pigmentary maculopathy, a type of retinal damage. While this condition does not appear to be widespread, it can lead to permanent vision loss or even blindness. Her lawsuit alleges that Elmiron was marketed to the medical community as a safe treatment for osteoarthritis and IC, and that it contained no warnings about the potential adverse side effects. In fact, Janssen’s website lists a variety of side effects, but does not mention the risk of permanent retinal damage.

Tina Pisco filed a lawsuit against Johnson & Johnson in the U.S. District Court for the Eastern District of Pennsylvania, alleging that Elmiron caused serious eye damage. She claims that the drug maker did not warn about this risk and put thousands of women at risk of losing their sight.

See also  10 Reasons Manga Is Better Than Anime

Deborah Quick’s Elmiron eye damage lawsuit

In October 2021, Deborah Quick filed an Elmiron eye damage lawsuit against Janssen Pharmaceuticals. She alleges that prolonged use of the drug caused damage to her retina. She was prescribed the drug in 2002 and took it daily for the remainder of her life, until March 2020. She says that she developed macular degeneration as a result of the medication.

The lawsuit alleges that Janssen failed to warn about the dangerous side effects of Elmiron. The company knew about the risks associated with the medication, but hid them from physicians and patients. However, it’s not clear whether Janssen is at fault for the damage to Quick’s eyes.

While there are a number of Elmiron lawsuits pending in the federal court, the pace of new cases has slowed over the past month. Elmiron-related eye damage lawsuits total over 1,700 in the federal class action and 170 in state court. Meanwhile, the IC drug market is expected to grow by 50 percent over the next six years. This year, the IC drug market will grow 6.6%, according to estimates.

Steps to file an Elmiron eye damage lawsuit

The first step in filing a successful Elmiron eye damage lawsuit is to determine the type of damage that you’ve suffered. If you’re suffering from permanent vision loss, you should contact a lawyer as soon as possible to get started on the claims process. If your vision is permanently damaged, it may take several years to reach a settlement. The sooner you begin the process, the sooner your case can be resolved. Typically, you can get a free consultation with a lawyer who can review your case.

See also  Why Pregnancy Care Class Ideal Choices for Parents

The next step is to gather evidence to support your claim. You will need to provide evidence that the Elmiron medication caused vision damage. You can prove your claims by collecting medical records and providing other evidence. Remember that your chances of receiving a settlement are greatly reduced if you file your case after the Virginia statute of limitations has passed.

A reputable law firm can help you get the compensation you deserve. Pendleton Law has experience against powerful organizations like Janssen, and can help you hold the company accountable. After filing your complaint, your attorney will send a summons to the pharmaceutical company’s representative. The representative should respond within a month.


0 Comments

Your email address will not be published. Required fields are marked *